Work

Canagliflozin, a novel inhibitor of sodium glucose co‐transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects

Year: 2011

Type: article

Study design: Clinical Trial

Source: Diabetes Obesity and Metabolism

DOI: 10.1111/j.1463-1326.2011.01406.x

Authors: S. Sha, D. Devineni, A. Ghosh, D. Polidori, S. Chien, D. Wexler, K. Shalayda, K. Demarest, P. Rothenberg

Institution: Janssen Research & Development (United States)

Language: English

Topic: Diabetes Treatment and Management

Subfield: Endocrinology, Diabetes and Metabolism

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W1997018189

FWCI: 19.52

Cites: 8

Cited by: 300

Related to: 10